Workshop: Inflammatory processes

Question 1

What are the biological treatments for rheumatoid arthritis?

Answer 1

Anti-TNF-a: e.g., infliximab

Anti-IL-6: e.g., sirukumab

Anti-IL-6 receptor: e.g., tocilizumab

Anti-CD20: e.g. rituximab

Anti-GM-CSF: e.g., otilimab – recent approach

Anti-GM-CSF receptor a: mavrilimumab – recent approach

Targeting IL-1: modest efficacy

Targeting IL-12/15/17/20/22/23: little/no efficacy

Question 2

What are the biological treatments for Systemic Lupus Erythematosus?

Answer 2

• Anti-CD20: e.g. rituximab
• Anti-BAFF: e.g., belimumab
• Anti-CD22: e.g., epratuzumab
• All have limited/modest effects (tendency to be last resort treatments)

Question 3

What are the biological treatments against Multiple Sclerosis?

Answer 3

• Anti-a4-integrin: e.g. natalizumab
• Anti-CD20: e.g., rituximab
• Anti-CD52: alemtuzumab – limited efficacy/notable adverse effects
• LINGO-1: opicinumab: under investigation/some effects
• Discontinued: targeting of BAFF, CD25, CD3, IL-17 receptor, IL-12p40

Question 4

What are the biological treatments against Type 1 diabetes?

Answer 4

• Anti-CD3: e.g., otelixizumab – variable but generally not sustainable effects
• Anti-CD20: rituximab – initial effect (e.g., less insulin required) but not sustained
• Currently being investigated: targeting IL-12p40/IL-6

Question 5

What are the biological treatments against Inflammatory Bowel Disease?

Answer 5

• Anti-TNF-a: e.g., infliximab, adalimumab
• Anti-a4-integrin, e.g., natalizumab
• Anti-IL-12p40: various mabs tested (e.g., ABT 874; ustekinumab) with variable results

Question 6

What are the biological treatments against Cardiovascular Diseases?

Answer 6

Anti-IL-1b (canakinumab) and anti-IL-6R (tocilizumab) in clinical trials

Anti-TNF-a: e.g., infliximab a possibility?

Anti-PKSC9 (can lower LDL-cholesterol levels), e.g., evolizumab

Anti-phosphorylcholine?

Question 7

What are the biological treatments against asthma?

Answer 7

Anti-IgE: e.g., omalizumab

Anti-IL-5: e.g., mepolizumab

Anti-IL-4Ra: e.g., dupilumab

Anti-IL-13: e.g., lebrikizumab

Anti-IL-17R: e.g., brodalumab – limited efficacy, neutrophilic asthma

Anti-TNF-a, e.g., infliximab – limited efficacy, neutrophilic asthma

Question 8

What are the biological treatments against COPD?

Answer 8

Anti-TNF-a, e.g., infliximab – generally not effective

Anti-IL-8, e.g., ABX-IL-8 – generally not effective

Anti-IL-5, e.g., mepolizumab – generally not effective